

RESEARCH

Open Access



# Elevated high-sensitivity C-reactive protein levels increase the risk of new-onset cardiac conduction disorders

Lili Wu<sup>1,3†</sup>, Meimei Wu<sup>2†</sup>, Dandan Zhao<sup>3†</sup>, Shuohua Chen<sup>4</sup>, Guodong Wang<sup>4</sup>, Lina Xu<sup>3</sup>, Yujing Wang<sup>3</sup>, Lina An<sup>3</sup>, Shouling Wu<sup>4\*</sup>, Congliang Miao<sup>3\*</sup> and Jiang Hong<sup>3\*</sup>

## Abstract

**Background** Previous studies have reported that inflammatory responses can promote the onset of cardiovascular diseases; however, its association with cardiac conduction disorders remains unclear. The present community-based cohort study aimed to elucidate the effects of inflammatory responses on the risk of developing cardiac conduction disorders.

**Methods** After the exclusion of participants failing to meet the inclusion criteria, 86,234 eligible participants (mean age:  $50.57 \pm 11.88$  years) were included. The participants were divided into high-sensitivity C-reactive protein (hsCRP)  $\leq 3$  mg/L, and hsCRP  $> 3$  mg/L groups based on hsCRP values. Multivariate Cox proportional hazard model was used to analyze the relationship between inflammatory responses and various cardiac conduction disorders.

**Results** After adjusting for confounding factors, we observed that compared with the hsCRP  $\leq 3$  mg/L group, the hsCRP  $> 3$  mg/L group exhibited increased risks of atrioventricular block (hazard ratio [HR]:1.64, 95%confidence interval [CI] 1.44–1.87) and left (HR:1.25, 95% CI 1.07–1.45) and right bundle branch block (HR:1.31, 95% CI 1.17–1.47). Moreover, the risk of various cardiac conduction disorders increased for every 1 standard deviation increase in log (hsCRP). The restricted cubic spline function confirmed a linear relationship between log (hsCRP) and the risk of developing cardiac conduction disorders (All nonlinearity  $P > 0.05$ ).

**Conclusions** High hsCRP levels are an independent risk factor for cardiac conduction disorders, and hsCRP levels are dose-dependently associated with the risk of conduction disorders. Our study results may provide new strategies for preventing cardiac conduction disorders.

**Keywords** Inflammation, Conduction disorders, High-sensitivity C-reactive protein, Atrioventricular block, Bundle branch block

<sup>†</sup>Lili Wu, Meimei Wu, and Dandan Zhao share first authorship.

\*Correspondence:

Shouling Wu

drwusl@163.com

Congliang Miao

mcl15917908206@163.com

Jiang Hong

jhong.pku@163.com

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Introduction

Cardiac conduction disease is a condition characterized by permanent or temporary disruptions in the transmission of electrical impulses within the cardiac conduction system. These disruptions can result from structural or functional abnormalities occurring at various levels of the cardiac conduction system. Notably, it often presents as bradycardia and is quite prevalent. Recent data from different European countries has revealed that prolonged PR intervals are observed in 1.9% to 3.7% of cases [1–3]. In China, in the year 2018, the prevalence of atrioventricular blocks was approximately 7.06% [4]. Previous studies have established a link between cardiac conduction disorders and an elevated risk of adverse cardiac outcomes. For instance, findings from the Framingham Heart Study indicate that a prolonged PR interval (> 200 ms) is associated with a 1.44-fold increase in the risk of all-cause mortality [5]. Furthermore, the Cardiovascular Health Study has reported that a left anterior branch block is linked to a 2.43-fold increased risk of heart failure and a 1.57-fold increased risk of all-cause mortality [6]. Despite the evident association between cardiac conduction disorders and poor prognosis, research on the risk factors and prognosis of these disorders is limited. Our investigation of the PubMed database, spanning from 2000 to 2023, uncovered fewer than 10 prospective cohort studies focusing on the risk factors and prognosis of this condition.

Although a few studies have identified the risk factors for cardiac conduction disorders, including advanced age, male gender, hypertension, and diabetes [7–11], they do not comprehensively explain the risk of their development. Myocardial fibrosis is thought to be an important pathological substrate for the development of cardiac conduction disorders [12, 13], which can interfere with all the basic electrophysiological mechanisms leading to arrhythmogenesis, including delayed action potential propagation, afterdepolarizations, re-entry, and increased ectopic automaticity [14]. Furthermore, inflammatory responses can promote the formation and development of myocardial fibrosis via electrical and structural remodeling [13, 15]. However, to the best of our knowledge, very few cohort studies have demonstrated if inflammatory responses can increase the risk of developing conduction disorders. Recently, Emilie et al. [16] reported that elevated high-sensitivity C-reactive protein (hsCRP) levels were associated with an increased risk of developing cardiac conduction disorders; however, their observations were in an elderly population with a small cohort size. Therefore, whether inflammation can increase the risk of developing conduction disorders in the general population remains unelucidated, which may provide a new possible direction of future strategies for preventing

cardiac conduction disorders. The present study aimed to determine the effects of inflammatory responses on the risk of developing cardiac conduction disorders using data from the Kailuan study.

## Subjects and methods

### Study population

In this prospective cohort study, a total of 11 hospitals in Kailuan General Hospital and affiliated hospitals conducted health check-ups for their active and retired employees from 2006, followed by follow-ups every 2 years; follow-up experiments included hsCRP measurement and a routine electrocardiography (ECG) examination. We enrolled Kailuan workers who participated in the 2006 health check-up as the participants. The inclusion criteria were as follows: (1) participants who attended the 2006 health check-up; (2) those with complete hsCRP and ECG data; and (3) those who agreed to participate in the study and signed the informed consent form. The exclusion criteria were as follows: (1) participants who attended the 2006 health check-up but did not participate in the follow-up check-ups; (2) those who were diagnosed with cardiac conduction disorders at the 2006 medical check-up; (3) those with arrhythmias such as atrial fibrillation, pre-excitation syndrome, and ventricular tachycardia or those with permanent pacemaker implantation; individuals with a previous diagnosis of congestive heart failure; and (5) individuals who have used beta-blockers and nondihydropyridine calcium channel blockers. This study has been approved by the Ethics Committee of Kailuan General Hospital in accordance with the Helsinki Declaration.

### Data collection

#### *Collection of general clinical characteristics, laboratory tests, and related definitions*

Information on the age, sex, disease status, and medication use of the study participants was collected using questionnaires. The methods and criteria for determining height, weight, and relevant biochemical indicators were according to a previous study [17]. Further, information on the diagnosis of new-onset myocardial infarction was collected via discharge records from all 11 hospitals in Kailuan, covering all participants in the Kailuan study. Smoking was defined as an average of at least 1 cigarette per day for the last 1 year, and for those who had quit smoking for < 1 year. Alcohol consumption was defined as an average of 100 mL of white wine ( $\geq 50\%$  alcohol) per day for the last 1 year, and for those who have abstained from drinking for < 1 year. Physical activity was defined as exercise for  $\geq 3$  times per week for  $\geq 30$  min. Body mass index (BMI) was calculated using the following formula:  $BMI = \text{weight}/\text{height}^2$  ( $\text{kg}/\text{m}^2$ ). Estimated

glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration formula [18]. Hypertension was defined as a systolic blood pressure (SBP) of  $\geq 140$  mm Hg and/or diastolic blood pressure (DBP) of  $\geq 90$  mmHg or the use of antihypertensive medication or history of hypertension despite a BP of  $< 140/90$  mmHg [19]. Diabetes mellitus was defined as fasting blood glucose (FBG) levels of  $\geq 7$  or  $< 7$  mmol/L but with a previous diagnosis of diabetes mellitus or those currently being treated with glucose-lowering drugs [20].

#### **Measurement of hsCRP levels and grouping**

The participants fasted for at least 8 h. On the day of the physical examination, 5 mL of fasting elbow venous blood was collected into EDTA vacuum tubes for the assay at 7:00–9:00 am. The plasma was separated and stored at  $-80^{\circ}\text{C}$  for further analysis. HsCRP levels were determined using a high-sensitivity enhanced immunoturbidimetric assay (Cias Latex CRP-H, Kanto Chemical Co. Inc., Tokyo, Japan), with intra- and interassay coefficients of variation of 6.53% and 4.78%, respectively, and a lower limit of detection of 0.1 mg/L. All plasma samples were tested at the central laboratory of Kailuan General Hospital using an automated analyzer (Hitachi 747, Hitachi, Tokyo, Japan).

As per the guideline [21], high hsCRP levels were defined as serum hsCRP levels of  $> 3$  mg/L; the study population was accordingly divided into the  $\text{hsCRP} \leq 3$  mg/L group, and the  $\text{hsCRP} > 3$  mg/L group.

#### **ECG measurements and definition of endpoint events**

Routine ECG measurements were performed at the 2006 health check-up and subsequent follow-up visits every 2 years. Subjects comfortably rested in the supine position in a quiet room for 5 min before a 12-lead ECG was taken for 10 s from 7:00–9:00 am. ECG measurements and diagnosis were completed by two ECG specialists. Various cardiac conduction disorders were defined according to the ECG diagnostic criteria of the Minnesota Code and the relevant US AHA guidelines [22–24], as detailed in Additional file 1: Table S1.

The primary endpoint was defined as any cardiac conduction disorder (aCCD), including I–III atrioventricular block (AVB), complete right bundle branch block (CRBBB), incomplete right bundle branch block (iRBBB), complete left bundle branch block (CLBBB), incomplete Left bundle branch block (iLBBB), left anterior fascicular block (LAFB), left posterior fascicular block (LPFB), and nonspecific intraventricular conduction disturbance (NS-IVCD). On the other hand, when defining each specific conduction disorder as an endpoint event, any AVB (aAVB) was defined as I, II, and III AVB; any bundle

branch block (aBBB) was defined as CRBBB, iRBBB, CLBBB, iLBBB, LAFB, and LPFB; any left bundle branch block (aLBBB) was defined as CLBBB, iLBBB, LAFB, and LPFB; and right bundle branch block (RBBB) was defined as CRBBB and iRBBB [22–24].

#### **Follow-up of endpoint events**

The date of completion of the 2006 health check-up was used as the starting point for follow-up experiments, and the first new cardiac conduction block was used as the endpoint event, with the time of occurrence as the endpoint time. For participants without any cardiac conduction disorders, the endpoint time was the date of the last follow-up visit. The occurrence of the endpoint event was recorded after reviewing the ECG follow-up results every 2 years for a total of six follow-up visits between 2008 and 2018, with a follow-up cutoff date of December 31, 2019.

#### **Statistical analysis**

Normally distributed data were expressed as mean  $\pm$  standard deviation. Two-group comparisons were performed using the two independent samples t-test, whereas multigroup comparisons were performed using a one-way analysis of variance. Nonnormally distributed data were expressed as median and quartile spacing (P25–P75). The Kruskal–Wallis rank sum test was used for between-group comparisons. Counting data were expressed as frequencies and percentages (n, %), and between-group comparisons were performed using the chi-squared test. The study population was divided into two groups based on whether the hsCRP level was  $>$  or  $< 3$  mg/L. The cumulative incidence of cardiac conduction disorder events in different groups was calculated using the Kaplan–Meier method and compared using the log-rank test. Multifactorial Cox proportional risk regression models were used to estimate hazard ratios (HRs) between different hsCRP subgroups or the HRs per one standard deviation increase in log (hsCRP) and 95% confidence intervals (CIs), and the age, sex, BMI, physical activity, smoking status, alcohol consumption, cholesterol (TC), uric acid (UA), eGFR at baseline, hypertension, diabetes mellitus, myocardial infarction at baseline or during follow-up, and uses of antihypertensive, lipid-lowering, and glucose-lowering drugs were corrected at baseline or during follow-up. The relationship between log (hsCRP) as a continuous variable and the risk of various conduction disorders was determined using restrictive triplicate strips after correcting for potential confounders. Subgroup analyses were conducted independently for age and gender to further pinpoint specific populations of interest. Sensitivity analysis was undertaken to validate the findings by reclassifying

participants with or without  $\text{hsCRP} \geq 1$  mg/L, by excluding those with  $\text{hsCRP}$  levels  $> 10$  mg/L, and by excluding individuals with a baseline MI history. This approach allowed us to once again compare the risk of developing cardiac conduction disorders between these two groups. Considering the long follow-up period of this study, a time-dependent Cox proportional risk regression model was established for the overall population to determine the effects of short-time exposure on the risk of developing cardiac conduction disorders. Furthermore, a competing risk model of death was established for the overall population, considering the effects of death on cardiac conduction disorder events during the follow-up. All data were analyzed using SAS statistical software (Version 9.4; SAS Institute, Cary, NC). Differences were considered statistically significant at a  $P$ -value of  $< 0.05$  (two-sided test).


## Results

In total, 101,510 individuals participated in the medical check-up in 2006. Among these individuals, 3768 were excluded due to incomplete high-sensitivity  $\text{hsCRP}$  data

at baseline, 6697 were excluded due to incomplete ECG data at both baseline and during the follow-up period, 3922 were excluded due to the presence of concurrent cardiac conduction disorders at baseline, and 889 were excluded due to the presence of combined conditions, including atrial fibrillation, ventricular tachycardia, pre-excitation syndrome, permanent pacemaker implantation, congestive heart failure, as well as the use of beta-blockers and nondihydropyridine calcium channel blockers at baseline. Finally, 86,234 individuals were included in the statistical analysis (Fig. 1).

## Baseline characteristics

The mean age of the participants was  $50.57 \pm 11.88$  years; 67,665 (78.47%) participants were men. The mean SBP was  $130.23 \pm 20.62$  mmHg, and the median  $\text{hsCRP}$  level was 0.80 (0.30–2.11) mg/L. A total of 70,002 (81.17%) participants were in the  $\text{hsCRP} \leq 3$  mg/L group and 16,232 (18.83%) participants were in the  $\text{hsCRP} > 3$  mg/L group. Age, BMI, TC, eGFR, FBG, SBP, DBP, number of heart attacks at baseline, proportion of participants with hypertension at baseline, proportion of participants with



**Fig. 1** Study flow chart

diabetes mellitus at baseline, and proportion of participants with taking antihypertensive, lipid-lowering, and glucose-lowering drugs at baseline were higher in the hsCRP > 3 mg/L group than in the hsCRP ≤ 3 mg/L group ( $P < 0.05$ ). The percentages of males, smoking, alcohol consumption and physical exercise in the hsCRP > 3 mg/L group were lower than those in the hsCRP ≤ 3 mg/L group ( $P < 0.05$ ); no statistical difference in uric acid levels between the two groups ( $P > 0.05$ ), see Table 1.

#### Effect of different hsCRP levels on the development of cardiac conduction disorders

At a median follow-up of 11.83 (8.87–13.04) years, 3614 cases of heart conduction disorders occurred, and the incidence of conduction disorders in the total population was 3.96/1000 person-years. Figure 2 demonstrates the cumulative incidence of the groups. The log-rank test

revealed a statistically significant difference in the cumulative incidence of the two groups ( $P < 0.0001$ ).






With the occurrence of heart block as a dependent variable, and the different hsCRP groupings as the independent variable or each 1 standard deviation increase in loghsCRP as the independent variable, the age, sex, BMI, physical activity, smoking, alcohol consumption, TC, UA, eGFR at baseline, hypertension, diabetes, myocardial infarction at baseline or during follow-up and antihypertensive, lipid-lowering and glucose-lowering medication at baseline or during follow-up were corrected. Multifactorial Cox regression analysis revealed a 1.40-fold (95% CI 1.29–1.51) increased risk of developing aCCD, 1.64-fold (95% CI 1.44–1.87) increased risk of developing aAVB, and 1.29-fold (95% CI = 1.18–1.42) increased risk of developing aBBB in the hsCRP > 3 mg/L group compared with the hsCRP ≤ 3 mg/L group. Furthermore, a 1.25-fold (95% CI 1.07–1.45) increased risk

**Table 1** Baseline and the follow-up characteristics of the study participants

	Overall	hsCRP ≤ 3 mg/L	hsCRP > 3 mg/L	P value
Participant (%)	86,234 (100)	70,002 (81.17)	16,232 (18.83)	
Age (year)	50.57 ± 11.88	49.76 ± 11.72	54.13 ± 11.93	< 0.0001
Male [n (%)]	67,665 (78.47)	55,317 (79.02)	12,348 (76.07)	< 0.0001
BMI (kg/m <sup>2</sup> )	25.07 ± 3.46	24.93 ± 3.38	25.66 ± 3.71	< 0.0001
TC (mmol/L)	4.95 ± 1.14	4.95 ± 1.14	4.97 ± 1.11	0.045
UA (μmol/L)	287.08 ± 82.65	287.04 ± 80.74	287.28 ± 90.42	0.735
eGFR (ml/min/1.73m <sup>2</sup> )	72.32 ± 25.25	71.85 ± 24.58	74.34 ± 27.85	< 0.0001
hsCRP (mg/L)	0.80 (0.30 ~ 2.11)	0.58 (0.23 ~ 1.19)	6.30 (4.12 ~ 9.20)	< 0.0001
FBG (mmol/L)	5.45 ± 1.62	5.42 ± 1.52	5.57 ± 1.94	< 0.0001
SBP (mmHg)	130.23 ± 20.62	129.56 ± 20.31	133.10 ± 21.68	< 0.0001
DBP (mmHg)	83.38 ± 11.67	83.19 ± 11.58	84.21 ± 11.98	< 0.0001
Smoking [n (%)]	33,835 (39.24)	28,490 (40.70)	5345 (32.93)	< 0.0001
Drinking [n (%)]	34,921 (40.50)	29,577 (42.25)	5344 (32.92)	< 0.0001
Physical activity [n (%)]	76,734 (88.98)	63,306 (90.43)	13,428 (82.73)	< 0.0001
Proportions of relevant diseases or taking relevant medications at baseline				
Myocardial Infarction [n (%)]	965 (1.12)	732 (1.05)	233 (1.44)	< 0.0001
Hypertension [n (%)]	36,992 (42.90)	28,869 (41.24)	8123 (50.04)	< 0.0001
Diabetes [n (%)]	7659 (8.88)	5708 (8.15)	1951 (12.02)	< 0.0001
Antihypertensive drugs [n (%)]	8891 (10.31)	6820 (9.74)	2071 (12.76)	< 0.0001
Hypoglycemic drugs [n (%)]	1915 (2.22)	1467 (2.10)	448 (2.76)	< 0.0001
Lipid-lowering drugs [n (%)]	757 (0.88)	559 (0.80)	198 (1.22)	< 0.0001
Proportions of relevant diseases or taking relevant medications during follow-up				
Myocardial infarction [n (%)]	1426 (1.65)	1016 (1.45)	410 (2.52)	< 0.0001
Hypertension [n (%)]	28,728 (33.31)	23,608 (33.72)	5120 (31.54)	< 0.0001
Diabetes [n (%)]	11,943 (13.85)	9336 (13.34)	2607 (16.06)	< 0.0001
Antihypertensive drugs [n (%)]	12,843 (14.89)	9640 (13.77)	3203 (19.73)	< 0.0001
Hypoglycemic drugs [n (%)]	4778 (5.54)	3285 (4.69)	1493 (9.19)	< 0.0001
Lipid-lowering drugs [n (%)]	2087 (2.42)	1530 (2.18)	557 (3.43)	< 0.0001

The measurement data of normal distribution were expressed as mean ± SD. The measurement data of skewed distribution were expressed as median (p25 ~ p75), and the counting data were expressed as number of cases (%). BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; hsCRP, high sensitivity C reactive protein; SBP, systolic blood pressure; TC, cholesterol; UA, uric acid



**A** Any cardiac conduction disorder**B** Any atrioventricular block**C** Any bundle branch block**D** Any left bundle branch block**E** Right bundle branch block

**Fig. 2** Cumulative incidence of the conduction disorders. **A**, Any cardiac conduction disorder; **B**, Any atrioventricular block; **C**, Any bundle branch block; **D**, Any left bundle branch block; **E**, Right bundle branch block

of developing aLBBB and 1.31-fold (95% CI 1.17–1.47) increased risk of developing RBBB was observed. For each standard deviation increase in log (hsCRP), the risk of developing aCCD increased by 1.13-fold (95% CI 1.10–1.18), aAVB increased by 1.23-fold (95% CI 1.15–1.31), aBBB increased by 1.10-fold (95% CI 1.06–1.15), aLBBB increased by 1.04-fold (95% CI 0.97–1.11) and RBBB increased by 1.13-fold (95% CI 1.08–1.19) (Table 2).

After correcting for the confounders mentioned above, a restricted spline curve was constructed by plotting log (hsCRP) against the risk of various cardiac conduction disorders. It revealed that log (hsCRP) was linearly correlated with the risk of aCCD, aAVB, aBBB, and RBBB (overall-association  $P < 0.0001$ , nonlinearity  $P > 0.05$ ) (Fig. 3).

### Subgroup analysis

To identify the priority population, we conducted subgroup analyses based on sex and age. Following adjustment for the same confounding factors, the Cox regression results revealed that the risk of developing aCCD was elevated in both the male and non-elderly

subgroups within the hsCRP > 3 mg/L category, when compared to the hsCRP ≤ 3 mg/L group. The HRs and their corresponding 95% CIs were 1.39 (1.28–1.51) and 1.44 (1.31–1.58), respectively (Table 3).

### Sensitivity analysis

Guidelines recommend [24] a cutoff value of < 1 mg/L for low-level hsCRP. We performed Cox regression analysis by performing regrouping at this cutoff value and observed a 1.19-fold increased risk of developing aCCD in the hsCRP ≥ 1 mg/L group compared with the hsCRP < 1 mg/L group (95% CI 1.11–1.27) after correcting for the same confounding factors. To mitigate the impact of acute inflammatory responses and MI on the final event outcome, we conducted a subsequent Cox regression analysis. This analysis involved the exclusion of individuals with baseline hsCRP > 10 mg/L and those with a history of MI, respectively. In our investigation, we observed a 1.41-fold increase in risk (95% CI 1.30–1.53) and 1.39-fold increase in risk (95% CI 1.29–1.5), respectively, for the development of aCCD condition among individuals with hsCRP > 3 mg/L when compared

**Table 2** Multivariate Cox proportional hazard model for the incidence of conduction disorders

	Cases/Total	Incidence/1000-person years	Model 1 HR (95% CI)	Model 2 HR (95%CI)	Model 3 HR (95%CI)	Model 4 HR (95%CI)
Any Cardiac conduction disorder						
hsCRP ≤ 3 mg/L	2674/70002	3.59 (3.46–3.74)	Reference	Reference	Reference	Reference
hsCRP > 3 mg/L	940/16232	5.60 (5.25–5.97)	1.43 (1.33–1.54)	1.43 (1.32–1.54)	1.41 (1.31–1.53)	1.40 (1.29–1.51)
log (hsCRP)/SD	3614/86234	3.96 (3.83–4.09)	1.17 (1.13–1.21)	1.15 (1.11–1.19)	1.14 (1.11–1.19)	1.13 (1.10–1.18)
Any Atrioventricular Block						
hsCRP ≤ 3 mg/L	781/70002	1.05 (0.98–1.13)	Reference	Reference	Reference	Reference
hsCRP > 3 mg/L	340/16232	2.02 (1.82–2.25)	1.74 (1.53–1.98)	1.70 (1.49–1.94)	1.69 (1.48–1.93)	1.64 (1.44–1.87)
log (hsCRP)/SD	1121/86234	1.23 (1.16–1.30)	1.29 (1.22–1.37)	1.25 (1.18–1.33)	1.24 (1.17–1.33)	1.23 (1.15–1.31)
Any Bundle- branch Block						
hsCRP ≤ 3 mg/L	1921/70002	2.58 (2.47–2.70)	Reference	Reference	Reference	Reference
hsCRP > 3 mg/L	615/16232	3.66 (3.38–3.96)	1.31 (1.19–1.43)	1.32 (1.20–1.45)	1.31 (1.18–1.43)	1.29 (1.18–1.42)
log (hsCRP)/SD	2536/86234	2.78 (2.67–2.89)	1.12 (1.08–1.16)	1.11 (1.07–1.16)	1.11 (1.06–1.15)	1.10 (1.06–1.15)
Any Left Bundle- branch Block						
hsCRP ≤ 3 mg/L	744/70002	1.00 (0.93–1.07)	Reference	Reference	Reference	Reference
hsCRP > 3 mg/L	241/16232	1.43 (1.26–1.63)	1.30 (1.12–1.51)	1.26 (1.08–1.46)	1.26 (1.08–1.46)	1.25 (1.07–1.45)
log (hsCRP)/SD	985/86234	1.08 (1.02–1.15)	1.07 (1.01–1.14)	1.05 (0.98–1.12)	1.04 (0.98–1.11)	1.04 (0.97–1.11)
Right Bundle- branch Block						
hsCRP ≤ 3 mg/L	1320/70002	1.77 (1.68–1.87)	Reference	Reference	Reference	Reference
hsCRP > 3 mg/L	420/16232	2.50 (2.27–2.75)	1.31 (1.16–1.46)	1.35 (1.20–1.51)	1.33 (1.18–1.49)	1.31 (1.17–1.47)
log (hsCRP)/SD	1740/86234	1.90 (1.82–2.00)	1.15 (1.09–1.20)	1.15 (1.09–1.21)	1.14 (1.09–1.20)	1.13 (1.08–1.19)


Model 1: Corrected for age and gender

Model 2: Corrected for baseline body mass index, physical activity, smoking, alcohol consumption, cholesterol, uric acid, estimated glomerular filtration rate, hypertension, diabetes mellitus, and myocardial infarction based on model 1

Model 3: Corrected for new-onset hypertension, diabetes mellitus, and myocardial infarction during the follow-up based on model 2

Model 4: Corrected for those taking antihypertensive, lipid-lowering, and glucose-lowering drugs at baseline or during the follow-up based on model 3





















HR, hazard ratio; Log (hsCRP)/SD, log-transformed for each standard deviation increase in hsCRP; CI, confidence interval



**Fig. 3** Restricted cubic spline curves of the effect of log (high-sensitivity C-reactive protein) on the onset of conduction disorders. **A**, Any cardiac conduction disorder; **B**, Any atrioventricular block; **C**, Any bundle branch block; **D**, Any left bundle branch block; **E**, Right bundle branch block



**Table 3** Subgroup analyses of the association between high-sensitivity C-reactive protein (hsCRP) and incidence of conduction disorders

	Cases /Total	Incidence density /1000-person years	hsCRP>3mg/L	HR (95%CI)
<b>Any Cardiac conduction disorder</b>				
Female	441/18569	2.11(1.92-2.32)		1.38(1.12-1.72)
Male	3173/67665	4.52(4.36-4.67)		1.39(1.28-1.51)
≤60years	2525/69676	3.31(3.18-3.45)		1.44(1.31-1.58)
>60years	1089/16558	7.26(6.84-7.71)		1.32(1.15-1.50)
<b>Any Atrioventricular Block</b>				
Female	145/18569	0.69(0.59-0.81)		1.57(1.09-2.28)
Male	976/67665	1.38(1.30-1.48)		1.65(1.44-1.91)
≤60years	768/69676	1.01(0.94-1.08)		1.73(1.47-2.04)
>60years	353/16558	2.35(2.12-2.61)		1.54(1.23-1.93)
<b>Any Bundle- branch Block</b>				
Female	300/18569	1.44(1.28-1.61)		1.29(0.99-1.69)
Male	2236/67665	3.18(3.05-3.32)		1.29(1.16-1.42)
≤60years	1775/69676	2.33(2.23-2.44)		1.31(1.17-1.48)
>60years	761/16558	5.07(4.73-5.45)		1.25(1.07-1.47)
<b>Any Left Bundle- branch Block</b>				
Female	106/18569	0.51(0.42-0.61)		1.23(0.79-1.91)
Male	879/67665	1.25(1.17-1.34)		1.24(1.06-1.46)
≤60years	656/69676	0.86(0.79-0.93)		1.30(1.07-1.58)
>60years	329/16558	2.19(1.97-2.44)		1.17(0.91-1.49)
<b>Right Bundle- branch Block</b>				
Female	218/18569	1.04(0.91-1.19)		1.19(0.87-1.64)
Male	1522/67665	2.17(2.06-2.28)		1.33(1.17-1.49)
≤60years	1236/69676	1.62(1.54-1.72)		1.32(1.15-1.52).
>60years	504/16558	3.36(3.08-3.67)		1.28(1.05-1.56)

Note: Corrected for age, sex, body mass index, physical activity, smoking, alcohol consumption, cholesterol, uric acid, estimated glomerular filtration rate, myocardial infarction at baseline or follow-up, hypertension at baseline or follow-up, diabetes mellitus at baseline or follow-up, and those taking medication at baseline or follow-up.

hsCRP≤3mg/L was used as reference in each subgroup.

HR, hazard ratio; CI, confidence interval.

to those with hsCRP≤3 mg/L. Additionally, for each increase in log (hsCRP), corresponding to an increase of 1 standard deviation, we identified a 1.14-fold elevated risk (95% CI 1.10–1.19) and 1.14-fold increased risk (95% CI 1.10–1.18), respectively, for the development of aCCD. These findings are in alignment with those obtained from the overall study population (Table 4).

The entire follow-up period of the present study was long. As follow-up was performed every 2 years, we divided the entire follow-up interval into six segments

using a 2-year interval. A time-dependent Cox regression model was used to analyze the short-term exposure effect of increased hsCRP levels on the risk of developing cardiac conduction disorder. After correcting for sex and time-varying risk factors such as age, BMI, smoking, alcohol consumption, physical activity, TC, UA, eGFR, hypertension, diabetes mellitus, myocardial infarction, and taking antihypertensive, lipid-lowering, and glucose-lowering drugs, we observed that compared with the hsCRP≤3 mg/L group, the risk of developing aCCD

**Table 4** Sensitivity analyses of the association between high-sensitivity C-reactive protein (hsCRP) and incidence of conduction disorders

	Cases/Total	Incidence/1000-person years	Model 1 HR (95% CI)	Model 2 HR (95%CI)	Model 3 HR (95%CI)	Model 4 HR (95%CI)
Regrouping of hsCRP						
Any Cardiac conduction disorder						
hsCRP < 1 mg/L	1800/48180	3.48 (3.33–3.65)	Reference	Reference	Reference	Reference
hsCRP ≥ 1 mg/L	1814/38054	4.58 (4.38–4.81)	1.26 (1.18–1.34)	1.22 (1.14–1.30)	1.21 (1.13–1.29)	1.19 (1.11–1.27)
Any Atrioventricular Block						
hsCRP < 1 mg/L	511/48180	0.99 (0.91–1.08)	Reference	Reference	Reference	Reference
hsCRP ≥ 1 mg/L	610/38054	1.54 (1.43–1.67)	1.49 (1.32–1.67)	1.38 (1.22–1.56)	1.37 (1.21–1.54)	1.33 (1.17–1.50)
Any Bundle- branch Block						
hsCRP < 1 mg/L	1307/48180	2.53 (2.39–2.67)	Reference	Reference	Reference	Reference
hsCRP ≥ 1 mg/L	1229/38054	3.11 (2.94–3.29)	1.17 (1.08–1.27)	1.15 (1.06–1.25)	1.14 (1.05–1.24)	1.13 (1.05–1.23)
Any Left Bundle- branch Block						
hsCRP < 1 mg/L	523/48180	1.01 (0.93–1.10)	Reference	Reference	Reference	Reference
hsCRP ≥ 1 mg/L	462/38054	1.17 (1.07–1.28)	1.08 (0.95–1.22)	1.03 (0.91–1.17)	1.03 (0.90–1.17)	1.02 (0.90–1.17)
Right Bundle- branch Block						
hsCRP < 1 mg/L	877/48180	1.69 (1.59–1.81)	Reference	Reference	Reference	Reference
hsCRP ≥ 1 mg/L	863/38054	2.18 (2.04–2.33)	1.24 (1.12–1.36)	1.24 (1.12–1.36)	1.22 (1.11–1.34)	1.21 (1.09–1.33)
Excluding hsCRP > 10 mg/L at baseline (N = 3342)						
Any Cardiac conduction disorder						
hsCRP ≤ 3 mg/L	2674/70002	3.59 (3.46–3.74)	Reference	Reference	Reference	Reference
hsCRP > 3 mg/L	758/12890	5.66 (5.27–6.08)	1.44 (1.33–1.57)	1.44 (1.33–1.56)	1.43 (1.32–1.55)	1.41 (1.30–1.53)
log (hsCRP)/SD	3432/82892	3.91 (3.78–4.04)	1.18 (1.14–1.23)	1.16 (1.12–1.21)	1.15 (1.11–1.20)	1.14 (1.10–1.19)
Any Atrioventricular Block						
hsCRP ≤ 3 mg/L	781/70002	1.05 (0.98–1.13)	Reference	Reference	Reference	Reference
hsCRP > 3 mg/L	274/12890	2.05 (1.82–2.30)	1.75 (1.52–2.02)	1.71 (1.49–1.97)	1.70 (1.47–1.96)	1.66 (1.44–1.92)
log (hsCRP)/SD	1055/82892	1.20 (1.13–1.28)	1.32 (1.23–1.41)	1.27 (1.18–1.36)	1.26 (1.17–1.36)	1.25 (1.16–1.34)
Any Bundle- branch Block						
hsCRP ≤ 3 mg/L	1921/70002	2.58 (2.47–2.70)	Reference	Reference	Reference	Reference
hsCRP > 3 mg/L	495/12890	3.69 (3.38–4.04)	1.32 (1.19–1.46)	1.33 (1.20–1.47)	1.32 (1.19–1.46)	1.31 (1.18–1.45)
log (hsCRP)/SD	2416/82892	2.75 (2.64–2.86)	1.13 (1.08–1.18)	1.12 (1.07–1.17)	1.11 (1.06–1.16)	1.10 (1.05–1.15)
Any Left Bundle- branch Block						
hsCRP ≤ 3 mg/L	744/70002	1.00 (0.93–1.07)	Reference	Reference	Reference	Reference
hsCRP > 3 mg/L	194/12890	1.45 (1.26–1.67)	1.32 (1.12–1.55)	1.28 (1.09–1.51)	1.28 (1.09–1.51)	1.27 (1.08–1.50)
log (hsCRP)/SD	938/82892	1.07 (1.00–1.14)	1.08 (1.00–1.16)	1.05 (0.97–1.12)	1.04 (0.97–1.12)	1.04 (0.97–1.12)
Right Bundle- branch Block						
hsCRP ≤ 3 mg/L	1320/70002	1.77 (1.68–1.87)	Reference	Reference	Reference	Reference
hsCRP > 3 mg/L	339/12890	2.53 (2.27–2.81)	1.32 (1.17–1.48)	1.36 (1.20–1.54)	1.34 (1.19–1.52)	1.33 (1.17–1.50)
log (hsCRP)/SD	1659/82892	1.89 (1.80–1.98)	1.16 (1.10–1.23)	1.16 (1.10–1.23)	1.15 (1.09–1.22)	1.14 (1.08–1.21)
Excluding Myocardial Infarction at baseline (N = 965)						
Any Cardiac conduction disorder						
hsCRP ≤ 3 mg/L	2629/69270	3.56 (3.43–3.70)	Reference	Reference	Reference	Reference
hsCRP > 3 mg/L	919/15999	5.54 (5.19–5.91)	1.43 (1.32–1.54)	1.43 (1.32–1.54)	1.42 (1.31–1.53)	1.39 (1.29–1.51)
log (hsCRP)/SD	3548/85269	3.93 (3.80–4.06)	1.17 (1.13–1.21)	1.15 (1.11–1.19)	1.15 (1.11–1.18)	1.14 (1.10–1.18)
Any Atrioventricular Block						
hsCRP ≤ 3 mg/L	770/69270	1.04 (0.97–1.12)	Reference	Reference	Reference	Reference
hsCRP > 3 mg/L	332/15999	2.00 (1.79–2.23)	1.73 (1.52–1.97)	1.69 (1.48–1.93)	1.68 (1.47–1.92)	1.63 (1.43–1.87)
log (hsCRP)/SD	1102/85269	1.22 (1.15–1.29)	1.28 (1.21–1.37)	1.25 (1.17–1.33)	1.24 (1.17–1.32)	1.22 (1.15–1.30)
Any Bundle- branch Block						
hsCRP ≤ 3 mg/L	1887/69270	2.56 (2.45–2.68)	Reference	Reference	Reference	Reference

**Table 4** (continued)

	Cases/Total	Incidence/1000-person years	Model 1 HR (95% CI)	Model 2 HR (95%CI)	Model 3 HR (95%CI)	Model 4 HR (95%CI)
hsCRP > 3 mg/L	601/15999	3.62 (3.34–3.92)	1.31 (1.18–1.43)	1.32 (1.20–1.45)	1.31 (1.19–1.44)	1.30 (1.18–1.43)
log (hsCRP)/SD	2488/85269	2.75 (2.65–2.86)	1.12 (1.01–1.17)	1.11 (1.07–1.16)	1.11 (1.06–1.15)	1.10 (1.06–1.15)
Any Left Bundle- branch Block						
hsCRP ≤ 3 mg/L	734/69270	0.99 (0.93–1.07)	Reference	Reference	Reference	Reference
hsCRP > 3 mg/L	231/15999	1.39 (1.23–1.58)	1.27 (1.09–1.48)	1.23 (1.05–1.43)	1.23 (1.06–1.44)	1.22 (1.05–1.43)
log (hsCRP)/SD	965/85269	1.97 (1.00–1.14)	1.07 (1.00–1.14)	1.04 (0.97–1.11)	1.04 (0.97–1.11)	1.03 (0.96–1.11)
Right Bundle- branch Block						
hsCRP ≤ 3 mg/L	1295/69270	1.75 (1.66–1.86)	Reference	Reference	Reference	Reference
hsCRP > 3 mg/L	414/15999	2.49 (2.27–2.75)	1.31 (1.17–1.46)	1.36 (1.21–1.52)	1.34 (1.19–1.51)	1.33 (1.18–1.49)
log (hsCRP)/SD	1709/85269	1.89 (1.81–1.98)	1.15 (1.09–1.21)	1.15 (1.10–1.21)	1.15 (1.09–1.20)	1.14 (1.01–1.20)

Model 1: Corrected for age and gender

Model 2: Corrected for baseline body mass index, physical activity, smoking, alcohol consumption, cholesterol, uric acid, estimated glomerular filtration rate, hypertension, diabetes mellitus, and myocardial infarction based on model 1

Model 3: Corrected for new-onset hypertension, diabetes mellitus, and myocardial infarction during the follow-up based on model 2

Model 4: Corrected for those taking antihypertensive, lipid-lowering, and glucose-lowering drugs at baseline or during the follow-up based on model 3

HR, hazard ratio; Log (hsCRP)/SD, log-transformed for each standard deviation increase in hsCRP; CI, confidence interval

increased 1.16-fold in the hsCRP > 3 mg/L group (95% CI 1.11–1.21). Furthermore, for every 1 standard deviation increase in log (hsCRP), the risk of developing aCCD increased by 1.04-fold (95% CI 1.02–1.05) (Additional file 1: Table S2).

Overall, 1632 all-cause deaths (1.89%) were reported in the present study. To eliminate the effect of all-cause mortality events on the outcomes during follow-up, we performed a competing risk of death model analysis on the total population; the results were consistent with those of the total population after correcting for the same confounders mentioned above (Additional file 1: Table S3).

## Discussion

In the present study, we confirmed that elevated hsCRP levels increase the risk of developing various cardiac conduction disorders and that hsCRP levels are associated with a dose–response risk of developing conduction disorders. This increased risk is independent of the traditional risk factors but age- and sex-dependent.

We identified high hsCRP levels as a risk factor for cardiac conduction disorders, with an increased risk of developing both atrioventricular block and right and left bundle branch block compared with the hsCRP ≤ 3 mg/L group. Moreover, the strength of the association between hsCRP levels and atrioventricular block was greater than that between hsCRP and bundle branch block. To the best of our knowledge, this is the first large-scale prospective cohort study to identify an association between hsCRP and cardiac conduction disorders. Only Emilie et al. [16] reported a 1.07-fold increased

risk of developing cardiac conduction disorders for every 10 mg/L increase in hsCRP levels in a cohort of 4314 older adults. Although there are no previous studies similar to ours, the association between high hsCRP and chronic noncommunicable diseases, including atherosclerotic cardiovascular disease, has been consistently confirmed [25–28]. Our findings expand the existing knowledge on chronic inflammation and the risk of developing cardiovascular diseases, as indicated by hsCRP levels.

We not only identified high hsCRP level as a risk factor for cardiac conduction disorders but also demonstrated a dose–response association between the inflammatory marker hsCRP and the risk of cardiac conduction disorders. For every 1 standard deviation increase in log (hsCRP), the risk of cardiac block, atrioventricular block, and right bundle branch block increased. Furthermore, the restricted spline function confirmed a linear association between log (hsCRP) and cardiac conduction block and atrioventricular block and right bundle branch block. The UK Biobank study [29] reported a dose-dependent association between hsCRP and the risk of bradyarrhythmia, with a 1.15-fold increased risk of bradyarrhythmia in the (3.0, 4.0) mg/L group, a 1.18-fold increased risk in the (4.0, 10.0) mg/L group, and a 1.30-fold increased risk in the ≥ 10.0 mg/L group compared with the hsCRP < 0.5 mg/L group. Moreover, a meta-analysis confirmed a linear association between hsCRP and the risk of cardiovascular diseases, stroke, and coronary heart disease [30]. Taken together, these studies indicate a dose–response relationship between inflammation levels and adverse cardiovascular outcomes, including conduction

disorders. We should attempt to decrease the risk of cardiovascular diseases, including conduction disorders, by reducing inflammation levels in the body by embracing a healthy lifestyle, including a healthy diet, exercise, smoking cessation, and weight loss [31, 32].

Furthermore, we noted that elevated hsCRP levels contribute to an augmented risk of cardiac conduction abnormalities. This risk manifests in a manner influenced by sex and age, with a more pronounced increase in cardiac conduction disorder risk observed in the male and younger age subgroups. Many studies have confirmed that the male sex is a risk factor for cardiac conduction disorders development [9–11, 33]. Data from Asian countries have revealed that male sex is associated with increased hsCRP levels [34, 35]; as a result, there may be a combined or superimposed effect of the inflammatory response among men for the development of cardiac conduction disorders, resulting in a more pronounced increased risk in this population. Previous studies have described a correlation between advanced age and increased risk of developing cardiac conduction disorders [10, 11]. However, in the present study, we observed that the pathogenic risk of high hsCRP level was higher in the younger subgroup. Studies have demonstrated that elevated hsCRP levels may be associated with traditional cardiovascular risk factors such as blood pressure, blood glucose levels, and obesity [36, 37]; therefore, the possibility of combined cardiovascular risk factors is high in the younger population with elevated hsCRP levels. In addition, studies have shown that the risk of developing cardiovascular diseases is associated with the age of onset of diabetes or hypertension; the younger the age of onset, the higher the relative risk of developing cardiovascular diseases [38, 39]. These findings may explain the higher risk of conduction disorders in the younger population than in the older population when they are simultaneously exposed to high hsCRP levels.

To determine the robustness of the study results, we performed Cox regression analysis via regrouping with or without  $\text{hsCRP} < 1 \text{ mg/L}$  in sensitivity analysis. We observed that the risk of developing any cardiac conduction disorder increased 1.19-fold (95% CI 1.11–1.27) in the  $\text{hsCRP} \geq 1 \text{ mg/L}$  group compared with the  $\text{hsCRP} < 1 \text{ mg/L}$  group, suggesting that even if individual hsCRP levels decreased to 1 mg/L, the risk of conduction disorder still increased. We conducted a repeated Cox regression analysis, excluding individuals with baseline  $\text{hsCRP} > 10 \text{ mg/L}$  or those with a history of MI. The outcomes of this analysis remained in accordance with the primary analysis. This suggests that the onset of conductive disorders owing to increased hsCRP levels was independent of whether the patient was complicated with an acute infection. We performed

time-dependent Cox regression analysis over a 2-year time period and observed a 1.16-fold (95% CI 1.11–1.21) increased risk of developing any cardiac conduction disorder in the  $\text{hsCRP} > 3 \text{ mg/L}$  group compared with the  $\text{hsCRP} \leq 3 \text{ mg/L}$  group, suggesting that decreasing the exposure to high hsCRP levels to 2 years could still increase the risk of developing conduction disorders. We considered the longer follow-up period and the possibility of competing risks of death; therefore, we conducted competing risk of death model analyses in the overall population; the results were consistent with those of the main analysis. Taken together, these sensitivity analyses confirm the robustness of our results.

A previous investigation proposed that CRP functions not only as an indicator of inflammation but also as a promoter of inflammation, thereby leading to myocardial fibrosis through the TLR4/NF- $\kappa$ B/TGF- $\beta$  pathway [40]. Another study revealed that CRP assumes a proarrhythmic role by directly influencing calcium homeostasis in cases of cardiac conduction disorders [41]. In our current research, we have provided evidence that elevated hsCRP levels can increase the risk of conduction disorders. Importantly, this elevated risk persists even after accounting for conventional cardiovascular risk factors such as hypertension, diabetes mellitus, and myocardial infarction. Therefore, we suggest that the aforementioned inflammatory responses may directly contribute to the development of conduction disorders. Our subgroup and sensitivity analyses yielded results consistent with those observed in the general population. These findings validate previous research and confirm the pivotal role played by CRP in the pathogenesis of these conditions. However, it is crucial to acknowledge that potential comorbidities and lifestyle habits associated with elevated hsCRP levels may also contribute to the onset of cardiac conduction disorders. These factors should be taken into consideration in the prevention of conduction-related diseases.

Several limitations of the present study has to be addressed. First, cardiac conduction disorders were diagnosed based on the ECG measurements taken at the medical check-up and did not include patients with conduction disorders who missed the follow-ups, which may have decreased the efficacy of the analysis. Second, the study population was employees of the Kailuan group, a predominantly male population, with limited extrapolation of the results; however, subgroup analysis of sex was conducted to compensate for this limitation. Third, hsCRP levels and other baseline assessments were only measured once; therefore, the results are not a representation of the long-term levels of the study population. Nevertheless, we performed time-dependent Cox regression analysis by considering changes in hsCRP and

other baseline variables during the follow-up period. The results were still statistically different, reducing the effect of the length of follow-up. Fourthly, it is essential to note that this study is observational in nature. Consequently, it cannot establish a definitive causal link between systemic inflammation and cardiac conduction disorders. To validate such a relationship, further confirmation through randomized controlled studies is warranted.

## Conclusions

The current study illustrates a significant connection between hsCRP levels and the risk of cardiac conduction disorders. These findings shed light on a potential new avenue for the prevention and management of cardiac conduction disorders.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12933-023-01987-1>.

**Additional file 1: Table S1.** Diagnostic criteria for the different conduction disorders. **Table S2.** Association between time-dependent high-sensitivity C-reactive protein (hsCRP) and risk of outcomes. **Table S3.** Competing risk model of death for the association between high-sensitivity C-reactive protein (hsCRP) and incidence of conduction disorders.

## Acknowledgements

We thank all study participants, their relatives, the members of the survey teams at the 11 regional hospitals of the Kailuan Medical Group; and the project development and management teams at the Shanghai Songjiang District Central Hospital, Shanghai General Hospital and the Kailuan Group.

## Author contributions

LW conducted the statistical analysis, interpreted the data and drafted the manuscript. MW performed the experiments and interpreted the data. DZ revised the manuscript for intellectual content. SC and GW interpreted the data. LX, YW, and LA revised the manuscript. SW, and JH had full access to all the data and take responsibility for the integrity of the data and the accuracy of the data analysis.

## Funding

No funding.

## Availability of data and materials

The data underlying this article will be shared on reasonable request to the corresponding authors.

## Declarations

### Ethics approval and consent to participate

The study protocol was approved by the Ethics Committee of Kailuan General Hospital. All participants provided written informed consent.

### Consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup>Department of Cardiology, Shanghai Songjiang District Central Hospital, Shanghai, China. <sup>2</sup>Department of Emergency and Critical Care Medicine, Shanghai Songjiang District Central Hospital, Shanghai, China. <sup>3</sup>Division

of Cardiovascular Diseases, Department of Emergency and Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100 Haining Road, Hongkou District, Shanghai 200080, China. <sup>4</sup>Department of Cardiology, Kailuan Hospital, North China University of Science and Technology, No. 57 Xinhua East Road, Tangshan 063001, China.

Received: 1 August 2023 Accepted: 7 September 2023

Published online: 30 September 2023

## References

1. Aro AL, Anttonen O, Kerola T, Junttila MJ, Tikkanen JT, Rissanen HA, et al. Prognostic significance of prolonged PR interval in the general population. *Eur Heart J*. 2014;35:123–9. <https://doi.org/10.1093/eurheartj/eh176>.
2. Awamleh GP, Alonso JJ, Graupner AC, Jiménez HR, Curcio RA, Talavera CP, et al. Investigators of the OFRECE Study Prevalence of electrocardiographic patterns associated with sudden cardiac death in the Spanish population aged 40 years or older: results of the OFRECE study. *Rev Esp Cardiol*. 2017;70:801–7. <https://doi.org/10.1016/j.rec.2016.11.039>.
3. Piwońska A, Piwoński J, Szczesnińska D, Drygas W. Population prevalence of electrocardiographic abnormalities: results of the Polish WAW-KARD study. *Kardiol Pol*. 2019;77:859–67. <https://doi.org/10.33963/KP.14911>.
4. Shan RQ, Ning Y, Ma Y, Liu SL, Wu J, Fan XH, et al. Prevalence and risk factors of atrioventricular block among 15 million Chinese health examination participants in 2018: a nation-wide cross-sectional study. *BMC Cardiovasc Disord*. 2021;21:289. <https://doi.org/10.1186/s12872-021-02105-3>.
5. Cheng S, Keyes MJ, Larson MG, McCabe EL, Newton-Cheh C, Levy D, et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. *JAMA*. 2009;301:2571–7. <https://doi.org/10.1001/jama.2009.888>.
6. Mandyam MC, Soliman EZ, Heckbert SR, Vittinghoff E, Marcus GM. Long-term outcomes of left anterior fascicular block in the absence of overt cardiovascular disease. *JAMA*. 2013;309:1587–8. <https://doi.org/10.1001/jama.2013.2729>.
7. Frimodt-Møller EK, Soliman EZ, Kizer JR, Vittinghoff E, Psaty BM, Biering-Sørensen T, et al. Lifestyle habits associated with cardiac conduction disease. *Eur Heart J*. 2023;44:1058–66. <https://doi.org/10.1093/eurheartj/ehac799>.
8. Saranda H, Andrim H, Morten M, Ulrik PB, Berit TP, Tommi BL, et al. Type 2 diabetes mellitus and higher rate of complete atrioventricular block: a Danish Nationwide Registry. *Eur Heart J*. 2023;44:752–61. <https://doi.org/10.1093/eurheartj/ehac662>.
9. Bussink BE, Holst AG, Jespersen L, Deckers JW, Jensen GB, Prescott E. Right bundle branch block: prevalence, risk factors, and outcome in the general population: results from the Copenhagen city heart study. *Eur Heart J*. 2013;34:138–46. <https://doi.org/10.1093/eurheartj/ehs291>.
10. Schneider JF, Thomas HE, Kreger BE, McNamara PM, Kannel WB. Newly acquired left bundle-branch block: the Framingham study. *Ann Intern Med*. 1979;90:303–10. <https://doi.org/10.7326/0003-4819-90-3-303>.
11. Jeong JH, Kim JH, Park YH, Han DC, Hwang KW, Lee DW, et al. Incidence of and risk factors for bundle branch block in adults older than 40 years. *Korean J Intern Med*. 2004;19:171–8. <https://doi.org/10.3904/kjim.2004.19.3.171>.
12. Wynn TA. Cellular and molecular mechanisms of fibrosis. *J Pathol*. 2008;214:199–210. <https://doi.org/10.1002/path.2277>.
13. Nguyen MN, Kiriazis H, Gao XM, Du XJ. Cardiac Fibrosis and Arrhythmogenesis. *Compr Physiol*. 2017;7:1009–49. <https://doi.org/10.1002/cphy.c160046>.
14. Kleber AG, Rudy Y. Basic mechanisms of cardiac impulse propagation and associated arrhythmias. *Physiol Rev*. 2004;84:431–88. <https://doi.org/10.1152/physrev.00025.2003>.
15. Azevedo PS, Polegato BF, Minicucci MF, Paiva SA, Zornoff LA. Cardiac remodeling: Concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment. *Arq Bras Cardiol*. 2016;106:62–9. <https://doi.org/10.5935/abc.20160005>.
16. Frimodt-Møller EK, Gottdiener JS, Soliman EZ, Kizer JR, Vittinghoff E, Psaty BM, et al. Inflammation and incident conduction disease. *J Am Heart Assoc*. 2023;12:027247. <https://doi.org/10.1161/JAHA.122.027247>.



17. Wu SL, Huang ZR, Yang XC, Zhou Y, Wang AX, Chen L, et al. Prevalence of ideal cardiovascular health and its relationship with the 4-year cardiovascular events in a northern Chinese industrial city. *Circ Cardiovasc Qual Outcomes*. 2012;5:487–93. <https://doi.org/10.1161/CIRCOUTCOMES.111.963694>.
18. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med*. 2012;367:20–9. <https://doi.org/10.1056/NEJMoa1114248>.
19. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International society of hypertension global hypertension practice guidelines. *Hypertension*. 2020;75:1334–57. <https://doi.org/10.1097/HJH.0000000000002453>.
20. Jia W, Weng J, Zhu D, Ji L, Lu J, Zhou Z, et al. Standards of medical care for type 2 diabetes in China 2019. *Diabetes Metab Res Rev*. 2019;35:e3158. <https://doi.org/10.1002/dmrr.3158>.
21. Thomas AP, George AM, Alexander RW, Anderson JL, Richard OC 3rd, Michael CQ, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for health-care professionals from the centers for disease control and prevention and the American heart association. *Circulation*. 2003;107:499–511. <https://doi.org/10.1161/01.cir.0000052939.59093.45>.
22. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American college of cardiology/American heart association task force on practice guidelines developed in collaboration with the American association for thoracic surgery and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2008;51:e1–62. <https://doi.org/10.1016/j.jacc.2008.02.032>.
23. Surawicz B, Childers R, Deal BJ, Gettes LS, Bailey JJ, Gorgels A, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. *Circulation*. 2009;119:e235–40. <https://doi.org/10.1016/j.jacc.2008.12.013>.
24. Prineas RJ, Crow RS, Zhang ZM. The Minnesota code manual of electrocardiographic findings: standards and procedures for ECG measurement in epidemiologic and clinical trials. 2nd ed. London: Springer-Verlag; 2010.
25. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for atrial fibrillation. *Circulation*. 2003;108:3006–10. <https://doi.org/10.1161/01.CIR.0000103131.70301.4F>.
26. Marott SC, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-Hansen A, et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. *J Am Coll Cardiol*. 2010;56:789–95. <https://doi.org/10.1016/j.jacc.2010.02.066>.
27. Wang A, Liu J, Li C, Gao J, Li X, Chen S, et al. Cumulative exposure to high-sensitivity c-reactive protein predicts the risk of cardiovascular disease. *J Am Heart Assoc*. 2017;6:e005610. <https://doi.org/10.1161/JAHA.117.005610>.
28. Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, et al. Inflammatory and cholesterol risk in the FOURIER Trial. *Circulation*. 2018;138:131–40. <https://doi.org/10.1161/CIRCULATIONAHA.118.034032>.
29. Yang XR, Zhao SH, Wang SH, Cao XL, Xu Y, Yan MC, et al. Systemic inflammation indicators and risk of incident arrhythmias in 478,524 individuals: evidence from the UK Biobank cohort. *BMC Med*. 2023;21:76. <https://doi.org/10.1186/s12916-023-02770-5>.
30. Yang X, Zhang D, Zhao Y, Liu D, Li Q, Guo C, et al. Association between serum level of C-reactive protein and risk of cardiovascular events based on cohort studies. *J Hum Hypertens*. 2021;35:1149–58. <https://doi.org/10.1038/s41371-021-00546-z>.
31. Kasisi C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. *J Am Coll Cardiol*. 2005;45:1563–9. <https://doi.org/10.1016/j.jacc.2004.12.077>.
32. Loprinzi PD. Dose–response association of moderate-to-vigorous physical activity with cardiovascular biomarkers and all-cause mortality: considerations by individual sports, exercise and recreational physical activities. *Prev Med*. 2015;81:73–7. <https://doi.org/10.1016/j.jypmed.2015.08.014>.
33. Thrainsdottir IS, Hardarson T, Thorgeirsson G, Sigvaldason H, Sigfusson N. The epidemiology of right bundle branch block and its association with cardiovascular morbidity—the Reykjavik Study. *Eur Heart J*. 1993;14:1590–6. <https://doi.org/10.1093/eurheartj/14.12.1590>.
34. Lee YJ, Lee JH, Shin YH, Kim JK, Lee HR, Lee DC. Gender difference and determinants of C-reactive protein level in Korean adults. *Clin Chem Lab Med*. 2009;47:863–9. <https://doi.org/10.1515/CCLM.2009.196>.
35. Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. *Am J Epidemiol*. 2001;153:1183–90. <https://doi.org/10.1093/aje/153.12.1183>.
36. Saito M, Ishimitsu T, Minami J, Ono H, Ohnishi M, Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. *Atherosclerosis*. 2003;167:73–9. [https://doi.org/10.1016/s0021-9150\(02\)00380-5](https://doi.org/10.1016/s0021-9150(02)00380-5).
37. Wang Z, Wang X, Chen Z, Zhang L, Zhu M. Distribution of High-Sensitivity C-Reactive Protein and Its relationship with other cardiovascular risk factors in the middle-aged Chinese population. *Int J Environ Res Public Health*. 2016;13:872. <https://doi.org/10.3390/ijerph13090872>.
38. Sung MK, Gyeongsil L, Seunggie C, Kyuwoong K, Su-Min J, Joung SS, et al. Association of early-onset diabetes, prediabetes and early glycaemic recovery with the risk of all-cause and cardiovascular mortality. *Diabetologia*. 2020;63:2305–14. <https://doi.org/10.1007/s00125-020-05252-y>.
39. Wang C, Yuan Y, Zheng M, Pan A, Wang M, Zhao M, et al. Association of age of onset of hypertension with cardiovascular diseases and mortality. *J Am Coll Cardiol*. 2020;75:2921–30. <https://doi.org/10.1016/j.jacc.2020.04.038>.
40. Sun WP, Wu YQ, Gao MY, Tian Y, Qi P, Shen YJ, et al. C-reactive protein promotes inflammation through TLR4/NF- $\kappa$ B/TGF- $\beta$  pathway in HL-1 cells. *Biosci Rep* 2019; 39: BSR20190888. <https://doi.org/10.1042/BSR20190888>.
41. Xie Y, Li Q, Zhang HF, Huang TC, Yang Y, Lin YQ, et al. Effect of C reactive protein on the sodium-calcium exchanger 1 in cardiomyocytes. *Exp Ther Med*. 2021;22:815. <https://doi.org/10.3892/etm.2021.10247>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

